CY1123345T1 - Αναλογα υποκατεστημενου (ε)-ν'-(1-φαινυλαιθυλιδενο) βενζοϋδραζιδιου ως αναστολεiς απομεθυλασης ιστονης - Google Patents
Αναλογα υποκατεστημενου (ε)-ν'-(1-φαινυλαιθυλιδενο) βενζοϋδραζιδιου ως αναστολεiς απομεθυλασης ιστονηςInfo
- Publication number
- CY1123345T1 CY1123345T1 CY20201100866T CY201100866T CY1123345T1 CY 1123345 T1 CY1123345 T1 CY 1123345T1 CY 20201100866 T CY20201100866 T CY 20201100866T CY 201100866 T CY201100866 T CY 201100866T CY 1123345 T1 CY1123345 T1 CY 1123345T1
- Authority
- CY
- Cyprus
- Prior art keywords
- substituted
- compounds
- benzohydrazide
- inhibitors
- phenylethylydene
- Prior art date
Links
- 108010033040 Histones Proteins 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- WARCRYXKINZHGQ-UHFFFAOYSA-N benzohydrazide Chemical class NNC(=O)C1=CC=CC=C1 WARCRYXKINZHGQ-UHFFFAOYSA-N 0.000 title 1
- 230000017858 demethylation Effects 0.000 title 1
- 238000010520 demethylation reaction Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 101001050886 Homo sapiens Lysine-specific histone demethylase 1A Proteins 0.000 abstract 2
- 102100024985 Lysine-specific histone demethylase 1A Human genes 0.000 abstract 2
- 101000615488 Homo sapiens Methyl-CpG-binding domain protein 2 Proteins 0.000 abstract 1
- 102100021299 Methyl-CpG-binding domain protein 2 Human genes 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- HAUVWRQIVOPGOE-FOWTUZBSSA-N n-[(e)-1-phenylethylideneamino]benzamide Chemical class C=1C=CC=CC=1C(/C)=N/NC(=O)C1=CC=CC=C1 HAUVWRQIVOPGOE-FOWTUZBSSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000010189 synthetic method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
- C07C311/46—Y being a hydrogen or a carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
- C07D295/26—Sulfur atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161523801P | 2011-08-15 | 2011-08-15 | |
| PCT/US2012/050948 WO2013025805A1 (en) | 2011-08-15 | 2012-08-15 | Substituted (e)-n'-(1-phenylethylidene) benzohydrazide analogs as histone demethylase inhiitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1123345T1 true CY1123345T1 (el) | 2022-03-24 |
Family
ID=47715455
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20201100866T CY1123345T1 (el) | 2011-08-15 | 2020-09-14 | Αναλογα υποκατεστημενου (ε)-ν'-(1-φαινυλαιθυλιδενο) βενζοϋδραζιδιου ως αναστολεiς απομεθυλασης ιστονης |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US8987335B2 (enExample) |
| EP (1) | EP2744330B1 (enExample) |
| JP (1) | JP6122006B2 (enExample) |
| KR (1) | KR101983537B1 (enExample) |
| CN (1) | CN103929960B (enExample) |
| AU (1) | AU2012296639B2 (enExample) |
| BR (1) | BR112014003382B1 (enExample) |
| CA (1) | CA2843609C (enExample) |
| CY (1) | CY1123345T1 (enExample) |
| DK (1) | DK2744330T3 (enExample) |
| EA (1) | EA026389B1 (enExample) |
| ES (1) | ES2821548T3 (enExample) |
| HK (1) | HK1200052A1 (enExample) |
| HR (1) | HRP20201433T1 (enExample) |
| HU (1) | HUE050962T2 (enExample) |
| IL (1) | IL230728A (enExample) |
| IN (1) | IN2014CN00961A (enExample) |
| LT (1) | LT2744330T (enExample) |
| MX (1) | MX356486B (enExample) |
| PL (1) | PL2744330T3 (enExample) |
| PT (1) | PT2744330T (enExample) |
| SG (1) | SG2014009609A (enExample) |
| SI (1) | SI2744330T1 (enExample) |
| SM (1) | SMT202000551T1 (enExample) |
| WO (1) | WO2013025805A1 (enExample) |
| ZA (1) | ZA201400881B (enExample) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9266838B2 (en) | 2011-08-15 | 2016-02-23 | University Of Utah Research Foundation | Substituted (E)-N′-(1-phenylethylidene)benzohydrazide analogs as histone demethylase inhibitors |
| DK2903968T3 (en) | 2012-10-02 | 2017-01-30 | Gilead Sciences Inc | INHIBITORS OF HISTON DEMETHYLASES |
| EP3170811A1 (en) | 2013-02-27 | 2017-05-24 | Gilead Sciences, Inc. | Ethyl pyridine-4-carboxylate compound as inhibitor of histone demethylases |
| EP2968282B1 (en) * | 2013-03-12 | 2018-05-09 | Celgene Quanticel Research, Inc. | Histone dementhylase inhibitors |
| ES2739814T3 (es) | 2013-06-19 | 2020-02-04 | Univ Utah Res Found | Compuestos de (3-(5-cloro-2-hidroxifenil)-1-benzoil-1H-pirazol sustituidos como inhibidores de histona desmetilasa |
| US9493442B2 (en) | 2014-02-13 | 2016-11-15 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
| WO2015123437A1 (en) | 2014-02-13 | 2015-08-20 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
| PE20161384A1 (es) | 2014-02-13 | 2016-12-28 | Incyte Corp | Ciclopropilaminas como inhibidores de lsd 1 |
| ME03654B (me) | 2014-02-13 | 2020-07-20 | Incyte Corp | Ciklopropilamini kao lsd1 inhibitori |
| US10807944B2 (en) | 2014-04-04 | 2020-10-20 | University Of Florida Research Foundation, Inc. | HDAC inhibitor compounds and methods of treatment |
| JP2017518312A (ja) * | 2014-06-05 | 2017-07-06 | ユニバーシティ・オブ・カンザス | マルメリン類似体および癌治療における使用方法 |
| WO2016007722A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
| WO2016007736A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Imidazopyrazines as lsd1 inhibitors |
| WO2016007727A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
| US9695168B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted imidazo[1,5-α]pyridines and imidazo[1,5-α]pyrazines as LSD1 inhibitors |
| CN107074807A (zh) | 2014-08-27 | 2017-08-18 | 吉利德科学公司 | 用于抑制组蛋白脱甲基酶的组合物和方法 |
| EP2993175A1 (en) | 2014-09-05 | 2016-03-09 | IEO - Istituto Europeo di Oncologia Srl | Thienopyrroles as histone demethylase inhibitors |
| CN106146361A (zh) * | 2015-03-16 | 2016-11-23 | 四川大学 | 茚-1-亚基磺酰基苯甲酰肼衍生物及其制备方法和用途 |
| MX373154B (es) | 2015-04-03 | 2020-04-22 | Incyte Holdings Corp | Compuestos heterocíclicos como inhibidores de demetilasa 1 específica de lisina (lsd1). |
| CN107849611A (zh) | 2015-06-12 | 2018-03-27 | 奥瑞泽恩基因组学股份有限公司 | 与lsd1抑制剂相关的生物标志物及其用途 |
| WO2017013061A1 (en) | 2015-07-17 | 2017-01-26 | Oryzon Genomics, S.A. | Biomarkers associated with lsd1 inhibitors and uses thereof |
| MX389824B (es) | 2015-08-12 | 2025-03-20 | Incyte Holdings Corp | Sales de un inhibidor de dimetilasa 1 especifica para lisina (lsd1). |
| JP7158023B2 (ja) | 2016-03-15 | 2022-10-21 | オリソン ヘノミクス エセ． アー． | 固形腫瘍の治療における使用のための、ｌｓｄ１阻害剤の組合せ |
| EP3430015B9 (en) | 2016-03-16 | 2025-12-31 | Oryzon Genomics, S.A. | METHODS FOR DETERMINING THE ENGAGEMENT OF A KDM1A TARGET AND CORRESPONDING USEFUL CHEMOPROBE |
| EP3445339B1 (en) | 2016-04-22 | 2023-08-23 | Incyte Corporation | Formulations of an lsd1 inhibitor |
| EP3246330A1 (en) | 2016-05-18 | 2017-11-22 | Istituto Europeo di Oncologia S.r.l. | Imidazoles as histone demethylase inhibitors |
| US11427543B2 (en) | 2016-07-19 | 2022-08-30 | The General Hospital Corporation | Compounds for targeting cancer stem cells |
| EP3535414A1 (en) | 2016-11-03 | 2019-09-11 | Oryzon Genomics, S.A. | Pharmacodynamic biomarkers for personalized cancer care using epigenetic modifying agents |
| EP3535420A1 (en) | 2016-11-03 | 2019-09-11 | Oryzon Genomics, S.A. | Biomarkers for determining responsiveness to lsd1 inhibitors |
| US20200069677A1 (en) | 2016-12-09 | 2020-03-05 | Constellation Pharmaceuticals, Inc. | Markers for personalized cancer treatment with lsd1 inhibitors |
| CN106831489B (zh) * | 2017-03-23 | 2018-04-17 | 郑州大学 | 苯环丙胺酰腙类化合物、制备方法及其应用 |
| SG11202000077RA (en) | 2017-08-03 | 2020-02-27 | Oryzon Genomics Sa | Methods of treating behavior alterations |
| EP3668877B1 (en) | 2017-08-18 | 2024-05-01 | Istituto Europeo di Oncologia S.r.l. | Indole derivatives as histone demethylase inhibitors |
| WO2019068326A1 (en) | 2017-10-05 | 2019-04-11 | Université D'aix-Marseille | INHIBITORS OF LSD1 FOR THE TREATMENT AND PREVENTION OF CARDIOMYOPATHIES |
| RS63124B1 (sr) | 2018-03-08 | 2022-05-31 | Incyte Corp | Aminopirazin diol jedinjenja kao pi3k-y inhibitori |
| WO2020010003A1 (en) | 2018-07-02 | 2020-01-09 | Incyte Corporation | AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS |
| WO2020047198A1 (en) | 2018-08-31 | 2020-03-05 | Incyte Corporation | Salts of an lsd1 inhibitor and processes for preparing the same |
| CN109793742A (zh) * | 2019-03-04 | 2019-05-24 | 四川大学华西医院 | 一种药物化合物应用 |
| CN113631164A (zh) | 2019-03-20 | 2021-11-09 | 奥莱松基因组股份有限公司 | 使用kdm1a抑制剂如化合物伐菲德司他治疗注意缺陷多动症的方法 |
| CN113613653A (zh) | 2019-03-20 | 2021-11-05 | 奥莱松基因组股份有限公司 | 治疗边缘型人格障碍的方法 |
| CN109758442B (zh) * | 2019-03-20 | 2021-08-17 | 武汉大学 | 二芳基酰肼类化合物在制备抗流感病毒药物中的应用 |
| JP2022546908A (ja) | 2019-07-05 | 2022-11-10 | オリゾン・ゲノミクス・ソシエダッド・アノニマ | Ｋｄｍ１ａ阻害剤を使用した小細胞肺がんの個別化された処置のためのバイオマーカーおよび方法 |
| US20220047528A1 (en) * | 2020-07-24 | 2022-02-17 | Salarius Pharmaceuticals Llc | Methods of inhibiting lysine-specific demethylase 1 (lsd-1) |
| EP3964204A1 (en) | 2020-09-08 | 2022-03-09 | Université d'Aix-Marseille | Lsd1 inhibitors for use in the treatment and prevention of fibrosis of tissues |
| TW202304416A (zh) | 2021-04-08 | 2023-02-01 | 西班牙商奧萊松基因組股份有限公司 | 用於治療骨髓癌的ｌｓｄ１抑制劑的組合 |
| US20250295660A1 (en) | 2022-05-09 | 2025-09-25 | Oryzon Genomics, S.A. | Methods of treating nf1-mutant tumors using lsd1 inhibitors |
| JP2025516647A (ja) | 2022-05-09 | 2025-05-30 | オリゾン・ゲノミクス・ソシエダッド・アノニマ | Ｌｓｄ１阻害薬を用いる悪性末梢神経鞘腫（ｍｐｎｓｔ）の治療法 |
| CN116077661B (zh) * | 2022-08-22 | 2024-09-27 | 沈阳药科大学 | Kdm1a抑制剂在制备治疗dnmt3a基因缺失癌症的药物中的用途 |
| AU2023385514A1 (en) | 2022-11-24 | 2025-07-10 | Oryzon Genomics, S.A. | Combinations of lsd1 inhibitors and menin inhibitors for treating cancer |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004525118A (ja) * | 2001-01-22 | 2004-08-19 | アルパイダ アーゲー | 新規ヒドラゾン類 |
| JP2002302472A (ja) * | 2001-01-31 | 2002-10-18 | Meiji Seika Kaisha Ltd | メイラード反応阻害剤 |
| EP1649852A1 (en) | 2003-07-16 | 2006-04-26 | Institute of Medicinal Molecular Design, Inc. | Chromatosis remedies |
| WO2006136008A1 (en) | 2005-05-24 | 2006-12-28 | University Health Network | Salicylic acid hydrazones as inhibitors of the erk mapkinase pathway and for the treatment of cancer |
| TW200800145A (en) * | 2005-08-26 | 2008-01-01 | Dekk Tec Inc | Hydrazone agents to treat cutaneous lesions |
| RU2008115539A (ru) | 2005-11-03 | 2009-12-10 | Рэдпойнт Био Корпорэйшн (Us) | Производные гидразона и их применение |
| US8338464B2 (en) | 2006-11-30 | 2012-12-25 | Albert Einstein College Of Medicine Of Yeshiva University | Small molecule inhibitors of BCL6 |
| JP2010518008A (ja) | 2007-02-02 | 2010-05-27 | レッドポイント バイオ コーポレイション | インスリンおよびｇｌｐ−１の放出を調節するｔｒｐｍ５阻害物質 |
| US8283351B2 (en) * | 2007-04-02 | 2012-10-09 | Institute For Oneworld Health | Cyclic and acyclic hydrazine derivatives compositions including them and uses thereof |
| WO2009027349A2 (en) * | 2007-08-24 | 2009-03-05 | Oryzon Genomics Sa | Treatment and prevention of neurodegenerative diseases |
| AR070898A1 (es) * | 2008-03-18 | 2010-05-12 | Solvay Pharm Bv | Derivados de arilsulfonil pirazolin carboxamidina como antagonistas de 5-ht6 |
| CA2729766A1 (en) | 2008-07-01 | 2010-01-07 | Zacharon Pharmaceuticals, Inc. | Heparan sulfate inhibitors |
| BRPI1006843A2 (pt) * | 2009-01-14 | 2017-05-30 | Dow Agrosciences Llc | composições fungicidas incluindo derivados de hidrazona e cobre |
| CA2727890A1 (en) | 2010-01-13 | 2011-07-13 | Norbert Kartner | Compounds, compositions and treatments for v-atpase related diseases |
-
2012
- 2012-08-15 ES ES12823540T patent/ES2821548T3/es active Active
- 2012-08-15 JP JP2014526170A patent/JP6122006B2/ja active Active
- 2012-08-15 SG SG2014009609A patent/SG2014009609A/en unknown
- 2012-08-15 US US13/586,603 patent/US8987335B2/en active Active
- 2012-08-15 HK HK15100490.8A patent/HK1200052A1/xx unknown
- 2012-08-15 WO PCT/US2012/050948 patent/WO2013025805A1/en not_active Ceased
- 2012-08-15 CN CN201280050736.9A patent/CN103929960B/zh active Active
- 2012-08-15 CA CA2843609A patent/CA2843609C/en active Active
- 2012-08-15 EP EP12823540.5A patent/EP2744330B1/en active Active
- 2012-08-15 MX MX2014001842A patent/MX356486B/es active IP Right Grant
- 2012-08-15 LT LTEP12823540.5T patent/LT2744330T/lt unknown
- 2012-08-15 AU AU2012296639A patent/AU2012296639B2/en active Active
- 2012-08-15 PL PL12823540T patent/PL2744330T3/pl unknown
- 2012-08-15 SI SI201231841T patent/SI2744330T1/sl unknown
- 2012-08-15 BR BR112014003382-0A patent/BR112014003382B1/pt active IP Right Grant
- 2012-08-15 IN IN961CHN2014 patent/IN2014CN00961A/en unknown
- 2012-08-15 EA EA201490453A patent/EA026389B1/ru unknown
- 2012-08-15 HR HRP20201433TT patent/HRP20201433T1/hr unknown
- 2012-08-15 HU HUE12823540A patent/HUE050962T2/hu unknown
- 2012-08-15 KR KR1020147006969A patent/KR101983537B1/ko active Active
- 2012-08-15 DK DK12823540.5T patent/DK2744330T3/da active
- 2012-08-15 SM SM20200551T patent/SMT202000551T1/it unknown
- 2012-08-15 PT PT128235405T patent/PT2744330T/pt unknown
-
2014
- 2014-01-30 IL IL230728A patent/IL230728A/en active IP Right Grant
- 2014-02-05 ZA ZA2014/00881A patent/ZA201400881B/en unknown
-
2015
- 2015-02-16 US US14/623,370 patent/US9555024B2/en not_active Expired - Fee Related
-
2020
- 2020-09-14 CY CY20201100866T patent/CY1123345T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1123345T1 (el) | Αναλογα υποκατεστημενου (ε)-ν'-(1-φαινυλαιθυλιδενο) βενζοϋδραζιδιου ως αναστολεiς απομεθυλασης ιστονης | |
| CY1122556T1 (el) | Υποκατεστημενα αναλογα ν-φαινυλπυριμιδιν-2- αμινης ως αναστολεις της κινασης axl | |
| CY1122988T1 (el) | Υπογλωσσια υμενια | |
| CY1121695T1 (el) | Ενωσεις και συνθεσεις ως αναστολεις κινασης c-kit | |
| IL243200B (en) | Converted analogs of (e)-n'-(1-phenylethylidene)benzohydrazide as histone demethylase inhibitors | |
| HRP20180239T1 (hr) | Deuterirani derivati benzokinolizina kao inhibitori vezikularnog monoaminskog transportera 2 | |
| WO2014194280A3 (en) | Novel suicidal lsd1 inhibitors targeting sox2-expressing cancer cells | |
| CY1118143T1 (el) | Ετεροκυκλικες ενωσεις χρησιμες ως αναστολεις της pdk1 | |
| CY1120438T1 (el) | Φαρμακευτικη συνθεση που περιλαμβανει μυο-ινοσιτολη και d-κιρο-ινοσιτολη | |
| CU24411B1 (es) | Compuesto derivado de benzamida sustituida con 1,3-tiazol-2-ilo útil para el tratamiento de trastornos neurogénicos | |
| BR112016008541A2 (pt) | composições úteis para tratar distúrbios relacionados a kit | |
| CY1118352T1 (el) | Νεα παραγωγα κυκλοεξυλαμινης με δρασεις β2 αδρενεργικου αγωνιστη και μ3 μουσκαρινικου ανταγωνιστη | |
| BRPI1012638B8 (pt) | métodos e intermediários para preparar agentes farmacêuticos | |
| GT201300254A (es) | Triazolopiridinas | |
| BR112014010713A2 (pt) | compostos com atividade nematicida | |
| CL2013002664A1 (es) | Compuestos derivados heterociclicos de amina; afines a receptores asociados a mina traza taar1; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento o profilaxis de la depresion, ansiedad, parkinson, trastorno bipolar, de hiperactividad con deficit atencional, relacionados con estres, y otros. | |
| BR112016008644A2 (pt) | Inibidor de dinamina 2 para uso no tratamento de uma miopatia centronuclear; método para identificar ou triar moléculas úteis no tratamento de uma miopatia centronuclear, de preferência, xlcnm; e composição farmacêutica | |
| CY1121081T1 (el) | Samidorphan (alks 33) σε συνδυασμο με βουπρενορφινη για την θεραπεια καταθλιπτικων διαταραχων | |
| CY1115577T1 (el) | Μεθοδος για την παρασκευη εναντιομερικως καθαρων αμινων | |
| CU24550B1 (es) | Compuestos de aza-indazol útiles en lesiones de tendones y/o ligamentos | |
| PH12015500795B1 (en) | N-(2-(cyclic amine)ethyl)benzamide derivatives as p2x7 inhibitors | |
| CY1119748T1 (el) | Υποκατασταθεντα 2-αλκυλ-1-οξο-ν-φαινυλ-3-ετεροαρυλ-1,2,3,4-τετραϋδροϊσοκινολιν-4-καρβοξαμιδια για ανθελονοσιακες θεραπειες | |
| BR112014012561A2 (pt) | mistura de aminas, processo para preparar uma mistura de aminas, composição de combustível, e, uso de uma mistura de aminas | |
| BR112014009760A2 (pt) | análogos de ácido siálico, seu uso e composição farmacêutica e composição farmacêutica de liberação sustentada os compreendendo | |
| EA201391586A1 (ru) | ИНГИБИТОРЫ 17α-ГИДРОКСИЛАЗЫ/C-ЛИАЗЫ |